As part of a multi-year RWE initiative, AMCP Research Institute partnered with IQVIA, payers, pharmaceutical companies, and others to design payer-focused RWE standards that were published in JMCP in September, 2025.
JMCP Findings - Stakeholder Insights on Cost, Quality, and Patient Voice in Managed Care for Wet AMDd
FINDINGS FROM THE AMCP MARKET INSIGHTS PROGRAM | October, 2024
Summary
Wet age-related macular degeneration is a condition that can lead to significant vision loss. It is treated with regular injections, which often work well at preventing vision loss but are a burden to patients with the condition. Health care organizations can help by better understanding this burden and doing what they can to lessen it. Importantly, this includes talking to doctors and patients to better understand their problems and their needs.
For more disease state research, view the Market Insights Program.
Related
AMCP’s guidance translates CMS’s expectations for patient centered, evidence informed formulary decisions into practical steps payers can act on today without adding unnecessary burden to P&T workflows.
Metabolic diseases drive rising costs and disparities, yet evidence‑based care remains inconsistent. AMCP is advancing guidance, education, and collaboration to support aligned coverage, equitable access, and improved outcomes.
Featured News & Resources
See Full CalendarUpcoming Events
AMCP offers a wide variety of educational opportunities, from events and webinars to online training.
